Kwang Dong Pharmaceutical Co., Ltd.
009290.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$343.65B
Close$
$-3624.08
153.3% downside
Current Fair Value
153.3% downsideOvervalued by 153.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $343.65 Billion |
|---|---|
| Enterprise Value | $559.47 Billion |
| Dividend Yield | $100.00 (1.45%) |
| Earnings per Share | $521 |
| Beta | 0.36 |
| Outstanding Shares | 58,186,000 |
Return
| Return on Equity | 3.42% |
|---|---|
| Return on Assets | 1.67% |
| Return on Invested Capital | -4.38% |
Valuation & Multiples
| P/E Ratio | 13.69 |
|---|---|
| PEG | 170.65 |
| Price to Sales | 0.23 |
| Price to Book Ratio | 0.56 |
| Enterprise Value to Revenue | 0.33 |
| Enterprise Value to EBIT | -16.26 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 0.47 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$244.30 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$244.30 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kwang Dong Pharmaceutical Co., Ltd.
1,022 employees
CEO: Sung-Won Choi Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutica...